Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Jacobso JACOBIO PHARMACEUTICALS GROUP CO . , LTD . HIGHLIGHTS 加科思 藥業 集團 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 1167 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 During the Reporting Period , our Group continued advancing the development of our drug candidates and business operations , including the following milestones and achievements : SHP2 Inhibitors Our lead drug development programs include two clinical - stage , oral , small - molecule allosteric SHP2 inhibitors ( JAB - 3068 and JAB - 3312 ) , for the potential treatment of cancers driven by RAS signaling pathway and immune checkpoint pathway . JAB - 3312 ( a SHP2 inhibitor ) The global Phase Ib / IIa trial of JAB - 3312 in combination with either a PD - 1 antibody or a MEK inhibitor has been initiated . The IND approval was granted by the U.S. FDA in December 2020. The IND application with the NMPA was also approved in May 2021 . The first two patients ' dosage in the U.S. has been completed in May 2021. Our Group received a milestone payment of US $ 20 million pursuant to the license and collaboration agreement with AbbVie in July 2021. For details , please refer to the below “ Collaboration with AbbVie " in this announcement . JAB - 3068 ( a SHP2 inhibitor ) The Phase I trial of JAB - 3068 for the treatment of solid tumors in the U.S. is in the close- out process . The Phase IIa trial of JAB - 3068 for the treatment of ESCC , HNSCC and NSCLC in China is currently ongoing . 1